Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 4696 AL 4710

Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease

Guzior N, Wieckowska A, Panek D, Malawska B.

Curr Med Chem. 2015;22(3):373-404. doi: 10.2174/0929867321666141106122628.

The role of chemical engineering in medicinal research including Alzheimer's

Kontogeorgis GM.

Adv Exp Med Biol. 2015;821:57-62. doi: 10.1007/978-3-319-08939-3_10.

Therapeutic Interventions for the Suppression of Alzheimer's Disease: Quest for a Remedy

Fazili NA, Naeem A, Ashraf GM, Hua GS, Kamal MA.

Curr Drug Metab. 2015;16(5):346-53. doi: 10.2174/1389200215999141125115749.

A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease

Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Velting DM.

Alzheimer Dis Assoc Disord. 2015 Apr-Jun;29(2):110-6. doi: 10.1097/WAD.0000000000000073.

Alzheimer's disease and other dementias: advances in 2014

Bateman R.

Lancet Neurol. 2015 Jan;14(1):4-6. doi: 10.1016/S1474-4422(14)70301-1.

A phase II trial of tideglusib in Alzheimer's disease

Lovestone S, Boada M, Dubois B, Hüll M, Rinne JO, Huppertz HJ, Calero M, Andrés MV, Gómez-Carrillo B, León T, del Ser T; ARGO investigators.

J Alzheimers Dis. 2015;45(1):75-88. doi: 10.3233/JAD-141959.

Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease

Kim TW.

Neurotherapeutics. 2015 Jan;12(1):132-42. doi: 10.1007/s13311-014-0325-7.

Dantrolene, a treatment for Alzheimer disease?

Liang L, Wei H.

Alzheimer Dis Assoc Disord. 2015 Jan-Mar;29(1):1-5. doi: 10.1097/WAD.0000000000000076.

[Multifunctional ligands--a new approach in the search for drugs against multi-factorial diseases]

Wichur T, Malawska B.

Postepy Hig Med Dosw (Online). 2015 Jan 2;69:1423-34.

Critical analysis of Alzheimer's amyloid-beta toxicity to mitochondria

Kaminsky YG, Tikhonova LA, Kosenko EA.

Front Biosci (Landmark Ed). 2015 Jan 1;20(1):173-97. doi: 10.2741/4304.

Brain metabolism and Alzheimer's disease: the prospect of a metabolite-based therapy

Thomas SC, Alhasawi A, Appanna VP, Auger C, Appanna VD.

J Nutr Health Aging. 2015 Jan;19(1):58-63. doi: 10.1007/s12603-014-0511-7.

A novel prescription for Alzheimer's disease: targeting hypercoagulable states

Maiese K.

Curr Neurovasc Res. 2015;12(1):1-3. doi: 10.2174/1567202612666150107162329.

Pin1 dysregulation helps to explain the inverse association between cancer and Alzheimer's disease

Driver JA, Zhou XZ, Lu KP.

Biochim Biophys Acta. 2015 Oct;1850(10):2069-76. doi: 10.1016/j.bbagen.2014.12.025. Epub 2015 Jan 10.

Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease

Walker D, Lue LF, Paul G, Patel A, Sabbagh MN.

Expert Opin Investig Drugs. 2015 Mar;24(3):393-9. doi: 10.1517/13543784.2015.1001490. Epub 2015 Jan 14.

Predictive factors of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease and mixed dementia: a one-year naturalistic study

Miranda LF, Gomes KB, Silveira JN, Pianetti GA, Byrro RM, Peles PR, Pereira FH, Santos TR, Assini AG, Ribeiro VV, Tito PA, Matoso RO, Lima TO, Moraes EN, Caramelli P.

J Alzheimers Dis. 2015;45(2):609-20. doi: 10.3233/JAD-142148.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias